


#41614
ver
519-01
PATENT APPLICATION



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: Dominquez et al.

Serial No. 09/732,546

Group Art Unit No.: 1614

Filed: December 8, 2000

Examiner: Not yet assigned

For: Integrin Inhibitors and Their Methods of Use

Docket No.: A-648

INFORMATION DISCLOSURE STATEMENT

Assistant Commissioner for Patents
Washington, D.C. 20231

Sir:

As a means of complying with the duty of disclosure, applicants submit a "List of References Cited by Applicant" on a modified PTO-1449 form and provides a copy of each of the listed references for consideration by the Examiner.

The information disclosure statement submitted herewith is being filed within three months of the filing date of the application or date of entry into the national stage of an international application or before the mailing date of a first Office action on the merits, or before the mailing of a first Office action after the filing of a request for continued examination under section 1.114, whichever event occurs last. 37 CFR 1.97(b).

Applicants requests consideration of this information and passage of the application to issue.

The Commissioner is hereby authorized to charge any filing fees which may be required or credit any overpayment to Deposit Account No. 01-0519 in the name of Amgen Inc.

Respectfully submitted,

Richard V. Person
Attorney for Applicants
Registration No.: 42,991
Phone: (805) 447-3299
Date: December 6, 2001

Please send all future correspondence to:

US Patent Operations/RVP
Dept. 4300, M/S 27-4-A
AMGEN INC.
One Amgen Center Drive
Thousand Oaks, California 91320-1799

CERTIFICATE OF MAILING

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail addressed to the Assistant Commissioner for Patents, Washington, DC 20231, on the date appearing below.

December 6, 2001

Date